{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:05:22Z","timestamp":1791198322706,"version":"4.1.0"},"reference-count":90,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurobiology of Aging"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.neurobiolaging.2012.07.018","type":"journal-article","created":{"date-parts":[[2012,8,24]],"date-time":"2012-08-24T18:00:27Z","timestamp":1345831227000},"page":"35-61","source":"Crossref","is-referenced-by-count":66,"title":["Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating \u201cclinical proof-of-concept\u201d for AAV-neurturin (CERE-120) in Parkinson's disease"],"prefix":"10.1016","volume":"34","author":[{"given":"Raymond T.","family":"Bartus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany L.","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamar","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian R.","family":"Kruegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Ostrove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/ana.22453","article-title":"Open-label surgical trials for Parkinson Disease: time for reconsideration","volume":"70","author":"Alterman","year":"2011","journal-title":"Ann. Neurol"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib2","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0074-7742(02)50083-0","article-title":"Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold?","volume":"50","author":"Apfel","year":"2002","journal-title":"Int. Rev. Neurobiol"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib3","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1001\/jama.284.17.2215","article-title":"Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial","volume":"284","author":"Apfel","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib4","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1212\/WNL.51.3.695","article-title":"Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy","volume":"51","author":"Apfel","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib5","series-title":"A phase 1 clinical trial of CERE-110 (AAV-NGF) gene delivery in Alzheimer's disease [abstract]","author":"Arvanitakis","year":"2007"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1096-9861(19971013)387:1<1::AID-CNE1>3.0.CO;2-5","article-title":"Carrier mediated delivery of NGF: alterations in basal forebrain neurons in aged rats revealed using antibodies against low and high affinity NGF receptors","volume":"387","author":"B\u00e4ckman","year":"1997","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib7","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.1523\/JNEUROSCI.16-17-05437.1996","article-title":"Systemic administration of a nerve growth factor conjugate reverses age-related cognitive dysfunction and prevents cholinergic neuron atrophy","volume":"16","author":"B\u00e4ckman","year":"1996","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib8","first-page":"14","article-title":"Long term evaluation of AAV\/AADC gene transfer in parkinsonian monkeys","volume":"299","author":"Bankiewicz","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib9","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.ymthe.2006.05.005","article-title":"Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC","volume":"14","author":"Bankiewicz","year":"2006","journal-title":"Mol. Ther"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2012.04.004","article-title":"Translating the therapeutic potential of neurotrophic factors to clinical \u201cproof of concept\u201d: a personal saga achieving a career-long quest","author":"Bartus","year":"2012","journal-title":"Neurobiol. Dis"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.nbd.2011.05.026","article-title":"Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease","volume":"44","author":"Bartus","year":"2011","journal-title":"Neurobiol. Dis"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/mds.23442","article-title":"Bioactivity of AAV-2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains","volume":"26","author":"Bartus","year":"2011","journal-title":"Mov. Disord"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib13","doi-asserted-by":"crossref","first-page":"S469","DOI":"10.1016\/S1353-8020(08)70052-X","article-title":"Issues regarding gene therapy products for Parkinson's disease: the development of CERE-120 (AAV-NTN) as one reference point","volume":"13","author":"Bartus","year":"2007","journal-title":"Parkinsonism Relat. Disord"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib14","first-page":"152","article-title":"The blood\u2013brain barrier as a target for pharmacological modulation","volume":"2","author":"Bartus","year":"1999","journal-title":"Curr. Opin. Drug Discov. Dev"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib15","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/0197-4580(89)90154-1","article-title":"Drug delivery to the brain: the problem lurking behind the problem?","volume":"10","author":"Bartus","year":"1989","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib16","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/0197-4580(89)90117-6","article-title":"Neurotrophic factors: can the degenerating brain be induced to heal itself?","volume":"10","author":"Bartus","year":"1989","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib17","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0197-4580(88)80097-6","article-title":"The need for common perspectives in the development and use of animal models for age-related cognitive and neurodegenerative disorders","volume":"9","author":"Bartus","year":"1988","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib18","first-page":"207","article-title":"Behavioral and pharmacological studies using animal models of aging: implications for studying and treating dementia of Alzheimer's type","author":"Bartus","year":"1983"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib19","series-title":"AAV-2-neurturin (CERE-120) and Parkinson's disease: the safety and feasibility of combined substantia nigral and putaminal stereotactic targeting via a Phase 1\/2b clinical trial in advanced Parkinson's disease","author":"Baumann","year":"2012"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib20","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S1474-4422(10)70256-8","article-title":"Gene therapy for Parkinson's disease: do we have the cure?","volume":"9","author":"Benabid","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0304-3940(99)00208-6","article-title":"Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by alpha-synuclein immunocytochemistry","volume":"265","author":"Braak","year":"1999","journal-title":"Neurosci. Lett"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib22","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/595830","article-title":"Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses","volume":"199","author":"Calcedo","year":"2009","journal-title":"J. Infect. Dis"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib23","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0006-8993(96)00398-8","article-title":"Atrophy of cholinergic basal forebrain neurons following excitotoxic cortical lesions is reversed by intravenous administration of an NGF conjugate","volume":"728","author":"Charles","year":"1996","journal-title":"Brain Res"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib24","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1006\/exnr.1998.6887","article-title":"Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor","volume":"154","author":"Choi-Lundberg","year":"1998","journal-title":"Exp. Neurol"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib25","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1006\/exnr.1997.6448","article-title":"Hyperplastic changes within the leptomeninges of the rat and monkey in response to chronic intracerebroventricular infusion of nerve growth factor","volume":"145","author":"Day-Lollini","year":"1997","journal-title":"Exp. Neurol"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib26","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1146\/annurev.neuro.31.061307.090711","article-title":"Role of axonal transport in neurodegenerative diseases","volume":"31","author":"De Vos","year":"2008","journal-title":"Annu. Rev. Neurosci"},{"issue":"Suppl 14","key":"10.1016\/j.neurobiolaging.2012.07.018_bib27","doi-asserted-by":"crossref","first-page":"S219","DOI":"10.1002\/mds.20957","article-title":"Deep brain stimulation: postoperative issues","volume":"21","author":"Deuschl","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-009-0046-7","article-title":"Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1 [erratum in 2010;98:9]","volume":"98","author":"Ding","year":"2010","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib29","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1159\/000017069","article-title":"Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease","volume":"9","author":"Eriksdotter J\u00f6nhagen","year":"1998","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib30","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/329065a0","article-title":"Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor","volume":"329","author":"Fischer","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib31","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cne.903630302","article-title":"Morphological and functional effects of intranigrally administered GDNF in normal rhesus monkeys","volume":"363","author":"Gash","year":"1995","journal-title":"J. Comp. Neurol"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib32","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/380252a0","article-title":"Functional recovery in parkinsonian monkeys treated with GDNF","volume":"380","author":"Gash","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib33","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/sj.mt.6300010","article-title":"Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease","volume":"15","author":"Gasmi","year":"2007","journal-title":"Mol. Ther"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib34","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.nbd.2007.04.003","article-title":"AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: Long-term efficacy and tolerability of CERE-120 for Parkinson's disease","volume":"27","author":"Gasmi","year":"2007","journal-title":"Neurobiol. Dis"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib35","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1089\/hum.2004.15.934","article-title":"Regulated Delivery of Glial Cell Line-Derived Neurotrophic Factor into Rat Striatum, Using a Tetracycline-Dependent Lentiviral Vector","volume":"15","author":"Georgievska","year":"2004","journal-title":"Hum. Gene Ther"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib36","doi-asserted-by":"crossref","first-page":"6437","DOI":"10.1523\/JNEUROSCI.1122-04.2004","article-title":"Overexpression of glial cell line-derived neurotrophic factor using a lentiviral vector induces time- and dose-dependent downregulation of tyrosine hydroxylase in the intact nigrostriatal dopamine system","volume":"24","author":"Georgievska","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib37","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nm850","article-title":"Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease","volume":"9","author":"Gill","year":"2003","journal-title":"Nat. Med"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib38","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/0197-4580(89)90118-8","article-title":"Function of neurotrophic factors in the adult and aging brain and their possible use in the treatment of neurodegenerative diseases","volume":"10","author":"Hefti","year":"1989","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib39","series-title":"Robust, stable, targeted, long-term neurturin expression and enhanced tyrosine hydroxylase labeling in Parkinson's disease brain 4 years following delivery of CERE-120 (AAV2-neurturin) to the human putamen","author":"Herzog","year":"2012"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib40","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s13346-011-0037-z","article-title":"Gene transfer provides a practical means for safe, long-term, targeted delivery of biologically active neurotrophic factor proteins for neurodegenerative diseases","volume":"1","author":"Herzog","year":"2011","journal-title":"Drug Deliv. Transl. Res"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib41","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1227\/01.NEU.0000340682.06068.01","article-title":"Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support CERE-120 for Parkinson's disease","volume":"64","author":"Herzog","year":"2009","journal-title":"Neurosurgery"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib42","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1038\/mt.2008.170","article-title":"Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum","volume":"16","author":"Herzog","year":"2008","journal-title":"Mol. Ther"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib43","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/mds.21503","article-title":"Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys","volume":"22","author":"Herzog","year":"2007","journal-title":"Mov. Disord"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib44","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1006\/exnr.1999.7175","article-title":"Differential in vivo effects of neurturin and glial cell-line-derived neurotrophic factor","volume":"160","author":"Hoane","year":"1999","journal-title":"Exp. Neurol"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib45","doi-asserted-by":"crossref","first-page":"4929","DOI":"10.1523\/JNEUROSCI.18-13-04929.1998","article-title":"Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons","volume":"18","author":"Horger","year":"1998","journal-title":"J. Neurosci"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib46","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1177\/01926230701481899","article-title":"Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-met HuGDNF) in rhesus monkeys","volume":"35","author":"Hovland","year":"2007","journal-title":"Tox. Pathologe"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib47","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1046\/j.1460-9568.2000.00274.x","article-title":"Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor","volume":"12","author":"Kirik","year":"2000","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib48","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1523\/JNEUROSCI.20-12-04686.2000","article-title":"Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system","volume":"20","author":"Kirik","year":"2000","journal-title":"J. Neurosci"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib49","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nrc1122","article-title":"Occurrence of leukaemia following gene therapy of X-linked SCID","volume":"3","author":"Kohn","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib50","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/ana.21032","article-title":"Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys","volume":"60","author":"Kordower","year":"2006","journal-title":"Ann. Neurol"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib51","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1126\/science.290.5492.767","article-title":"Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease","volume":"290","author":"Kordower","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib52","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/1531-8249(199909)46:3<419::AID-ANA21>3.0.CO;2-Q","article-title":"Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease","volume":"46","author":"Kordower","year":"1999","journal-title":"Ann. Neurol"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib53","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/384467a0","article-title":"Neurturin, a relative of glial-cell-line-derived neurotrophic factor","volume":"384","author":"Kotzbauer","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib54","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1023\/A:1012230113527","article-title":"New animal models to probe brain tumor biology, therapy, and immunotherapy: advantage and remaining concerns","volume":"53","author":"Lampson","year":"2001","journal-title":"J. Neuro Oncol"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib55","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/ana.20737","article-title":"Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease","volume":"59","author":"Lang","year":"2006","journal-title":"Ann. Neurol"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib56","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/mds.23544","article-title":"Parkinson's disease, primates, and gene therapy: vive la diff\u00e9rence?","volume":"26","author":"Lewis","year":"2011","journal-title":"Mov. Disord"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib57","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1126\/science.8493557","article-title":"GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons","volume":"260","author":"Lin","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib58","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jtbi.2007.09.009","article-title":"Prediction of convection-enhanced drug delivery to the human brain","volume":"250","author":"Linninger","year":"2008","journal-title":"J. Theor. Biol"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib59","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.biopsych.2009.02.009","article-title":"Role of ventral tegmental area glial cell line-derived neurotrophic factor in incubation of cocaine craving","volume":"66","author":"Lu","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib60","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1038\/mt.2009.196","article-title":"Tight long-term dynamic doxycycline responsive nigrostriatal GDNF using a single rAAV vector","volume":"17","author":"Manfredsson","year":"2009","journal-title":"Mol. Ther"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib61","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/mt.2009.45","article-title":"Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity","volume":"17","author":"Manfredsson","year":"2009","journal-title":"Mol. Ther"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib62","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S1474-4422(10)70254-4","article-title":"Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial","volume":"9","author":"Marks","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib63","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1474-4422(08)70065-6","article-title":"Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial","volume":"7","author":"Marks","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib64","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0197-4580(02)00022-2","article-title":"Effects of chronic intraputamenal infusion of glial cell line-derived neurotrophic factor (GDNF) in aged Rhesus monkeys","volume":"23","author":"Maswood","year":"2002","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib65","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1098\/rstb.1996.0039","article-title":"NGF as a mediator of inflammatory pain","volume":"351","author":"McMahon","year":"1996","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib66","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.neurobiolaging.2005.08.012","article-title":"Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease","volume":"27","author":"McNaught","year":"2006","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib67","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/ana.410390215","article-title":"A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis","volume":"39","author":"Miller","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib68","doi-asserted-by":"crossref","first-page":"12776","DOI":"10.1523\/JNEUROSCI.3463-09.2009","article-title":"Axonal transport defects in neurodegenerative diseases","volume":"29","author":"Morfini","year":"2009","journal-title":"J. Neurosci"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib69","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3171\/JNS-07\/07\/0074","article-title":"Convective delivery of glial cell line-derived neurotrophic factor in the human putamen","volume":"107","author":"Morrison","year":"2007","journal-title":"J. Neurosurg"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib70","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0301-0082(98)00059-8","article-title":"Distribution and retrograde transport of trophic factors in the central nervous system: functional implications for the treatment of neurodegenerative diseases","volume":"57","author":"Mufson","year":"1999","journal-title":"Prog. Neurobiol"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib71","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3171\/jns.1999.91.3.0447","article-title":"Intraventricular infusion of nerve growth factor as the cause of sympathetic fiber sprouting in sensory ganglia","volume":"91","author":"Nauta","year":"1999","journal-title":"J. Neurosurg"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib72","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1212\/WNL.60.1.69","article-title":"Implanted intracerebroventricular glial cell line-derived neurotrophic factor","volume":"60","author":"Nutt","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib73","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0006-8993(02)02934-7","article-title":"Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease","volume":"947","author":"Oiwa","year":"2002","journal-title":"Brain Res"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib74","first-page":"94","article-title":"Intrathecal ciliary neurotrophic factor delivery for treatment of amyotrophic lateral sclerosis (phase I trial)","volume":"40","author":"Penn","year":"1997","journal-title":"Neurosurgery"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib75","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1146\/annurev.neuro.29.051605.112929","article-title":"Neurotrophins: mediators and modulators of pain","volume":"29","author":"Pezet","year":"2006","journal-title":"Annu. Rev. Neurosci"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib77","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1126\/science.1068613","article-title":"Axonal self-destruction and neurodegeneration","volume":"296","author":"Raff","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib78","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2003.08.016","article-title":"Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer","volume":"80","author":"Raper","year":"2003","journal-title":"Mol. Genet. Metab"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib79","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1046\/j.1460-9568.2003.02456.x","article-title":"Long-term striatal overexpression of GDNF selectively downregulates tyrosine hydroxylase in the intact nigrostriatal dopamine system","volume":"17","author":"Rosenblad","year":"2003","journal-title":"Eur. J. Neurosci"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib80","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1046\/j.1460-9568.1999.00566.x","article-title":"Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle","volume":"11","author":"Rosenblad","year":"1999","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib81","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00401-004-0952-x","article-title":"Axonal transport defects: a common theme in neurodegenerative diseases","volume":"109","author":"Roy","year":"2005","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib82","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.expneurol.2006.07.015","article-title":"Point source concentration of GDNF may explain failure of phase II clinical trial","volume":"202","author":"Salvatore","year":"2006","journal-title":"Exp. Neurol"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib83","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0166-4328(93)90141-C","article-title":"Intracranial infusion of purified nerve growth factor to an Alzheimer patient: the first attempt of a possible future treatment strategy","volume":"57","author":"Seiger","year":"1993","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib84","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/mds.20861","article-title":"Crossroads in GDNF therapy for Parkinson's disease","volume":"21","author":"Sherer","year":"2006","journal-title":"Mov. Disord"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib85","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3171\/jns.2005.102.2.0216","article-title":"Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor","volume":"102","author":"Slevin","year":"2005","journal-title":"J. Neurosurg"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib86","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/ana.410260402","article-title":"Neurotrophic molecules","volume":"26","author":"Snider","year":"1989","journal-title":"Ann. Neurol"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib87","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1146\/annurev.neuro.24.1.1217","article-title":"Nerve growth factor signaling, neuroprotection, and neural repair","volume":"24","author":"Sofroniew","year":"2001","journal-title":"Annu. Rev. Neurosci"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib88","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1089\/hum.2009.103","article-title":"Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys","volume":"20","author":"Su","year":"2009","journal-title":"Hum. Gene Ther"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib89","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1097\/00001756-199806010-00027","article-title":"Neurturin protects dopaminergic neurons following medial forebrain bundle axotomy","volume":"9","author":"Tseng","year":"1998","journal-title":"Neuroreport"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib90","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nm1239","article-title":"A phase I clinical trial of nerve growth factor gene therapy for Alzheimer disease","volume":"11","author":"Tuszynski","year":"2005","journal-title":"Nat. Med"},{"key":"10.1016\/j.neurobiolaging.2012.07.018_bib91","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1046\/j.1529-8027.2001.01019.x","article-title":"A double-blind placebo-controlled clinical trial of recombinant human brain-derived neurotrophic factor (rhBDNF) in diabetic polyneuropathy","volume":"6","author":"Wellmer","year":"2001","journal-title":"J. Peripher. Nerv. Syst"}],"container-title":["Neurobiology of Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197458012004216?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197458012004216?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T03:41:36Z","timestamp":1562125296000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0197458012004216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":90,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S0197458012004216"],"URL":"https:\/\/doi.org\/10.1016\/j.neurobiolaging.2012.07.018","relation":{},"ISSN":["0197-4580"],"issn-type":[{"value":"0197-4580","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}